NantHealth’s (NYSE:NH) lock-up period is set to expire on Tuesday, November 29th. NantHealth had issued 6,500,000 shares in its initial public offering on June 2nd. The total size of the offering was $91,000,000 based on an initial share price of $14.00. After the expiration of NantHealth’s lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

NH has been the subject of a number of recent analyst reports. Canaccord Genuity reiterated a “buy” rating and issued a $17.00 target price on shares of NantHealth in a research report on Monday, September 19th. FBR & Co restated a “buy” rating on shares of NantHealth in a research report on Thursday, November 3rd. Finally, Zacks Investment Research upgraded shares of NantHealth from a “sell” rating to a “hold” rating in a research report on Friday, September 23rd. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. NantHealth presently has an average rating of “Buy” and a consensus price target of $18.00.

TRADEMARK VIOLATION NOTICE: This story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright legislation. The correct version of this story can be accessed at https://www.thecerbatgem.com/2016/11/26/nanthealth-incs-nh-lock-up-period-will-expire-on-november-29th.html.

NantHealth (NYSE:NH) opened at 12.54 on Friday. The stock’s 50 day moving average is $12.37 and its 200 day moving average is $12.58. The company’s market cap is $1.52 billion. NantHealth has a 52-week low of $9.67 and a 52-week high of $21.00.

Several hedge funds and other institutional investors have recently modified their holdings of NH. FMR LLC bought a new position in shares of NantHealth during the second quarter worth about $11,250,000. Wildcat Capital Management LLC bought a new position in shares of NantHealth during the second quarter worth about $3,008,000. Jefferies Group LLC bought a new position in shares of NantHealth during the second quarter worth about $6,943,000. Blackstone Group L.P. bought a new position in shares of NantHealth during the second quarter worth about $7,463,000. Finally, Emerald Advisers Inc. PA boosted its position in shares of NantHealth by 190.4% in the third quarter. Emerald Advisers Inc. PA now owns 630,701 shares of the company’s stock worth $8,294,000 after buying an additional 413,501 shares during the last quarter.

About NantHealth

NantHealth, Inc, formerly Nant Health, LLC, is an evidence-based, personalized healthcare company. The Company’s systems-based approach to personalized healthcare applies diagnostics tailored to specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with real-time biometric signal and phenotypic data to track patient outcomes and deliver medicine.

5 Day Chart for NYSE:NH

Receive News & Stock Ratings for NantHealth Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth Inc and related stocks with our FREE daily email newsletter.